FAQ on Quantum BioPharma Ltd.'s Phase 2 Trial Approval for FSD202 in MCAS Patients

What is the significance of Quantum BioPharma Ltd.’s recent ethics approval in Australia?

The approval allows Quantum BioPharma to begin a Phase 2 clinical trial for FSD202, a potential new treatment for chronic pain associated with Mast Cell Activation Syndrome (MCAS), a condition currently without a cure.

What is FSD202 and how does it work?

FSD202 is based on ultra-micronized palmitoylethanolamide (PEA) and targets inflammation-related conditions, offering a new therapeutic option for MCAS by potentially reducing pain and inflammation.

Who will participate in the Phase 2 trial of FSD202?

The trial will enroll 60 patients with chronic widespread musculoskeletal nociplastic pain associated with idiopathic Mast Cell Activation Syndrome (MCAS).

How will the Phase 2 trial be conducted?

It is a randomized, double-blind, placebo-controlled trial that will measure pain reduction over 56 days in participants.

Why is there an urgent need for treatments like FSD202?

MCAS is a debilitating disorder with no current cure, highlighting the need for safe and effective treatment alternatives to improve patients’ quality of life.

Where can I find more information about Quantum BioPharma Ltd. and its projects?

More information is available in the company’s newsroom at https://www.investorbrandnetwork.com/clients/quantum-biopharma-ltd/ and the full press release at https://ibn.fm/oNVFn.

What other projects is Quantum BioPharma Ltd. involved in?

Quantum BioPharma is focused on treating neurodegenerative and metabolic disorders, alcohol misuse disorders, and has a lead compound, Lucid-MS, for multiple sclerosis, among other projects.

How does Quantum BioPharma Ltd. contribute to the treatment of multiple sclerosis?

Through its subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is developing Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models of multiple sclerosis.